Axsome Therapeutics Debt 2024

Axsome Therapeutics Aktienanalyse

What does Axsome Therapeutics do?

Axsome Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of severe psychiatric and neurological disorders. The company was founded in 2012 and is headquartered in New York City. The history of Axsome Therapeutics began with the identification of a new molecule called AXS-05, which was developed as a potential antidepressant and treatment for Alzheimer's disease. The company utilized its proprietary technology platform to optimize the drug's properties and then began conducting clinical studies to evaluate the efficacy and safety of AXS-05 in patients with depression, Alzheimer's disease, and other neurological disorders. Axsome Therapeutics' business model is based on the identification and development of novel drug candidates through the use of knowledge about novel target molecules and innovative technologies. The company aims to rapidly and cost-effectively develop its drugs to quickly achieve commercial benefits from its developments. The company relies on collaboration with strategic partners and acquisitions for faster market entry. Axsome Therapeutics is divided into several business areas, each identifying and developing different drug candidates. For example, one area is the field of pain medicine, where the company is developing novel therapies for chronic pain and migraines. Another area is psychiatric disorders, where the company focuses on novel treatments for depression, anxiety disorders, bipolar disorder, and post-traumatic stress disorder. A third area is neurodegenerative diseases, where the company is researching new approaches to treating Alzheimer's disease and Parkinson's disease. Axsome Therapeutics has several products in the pipeline at various stages of clinical development. The most advanced product is the antidepressant AXS-05, which is currently being tested in Phase III clinical trials for the treatment of depression and Alzheimer's disease. AXS-05 has been deemed safe and well-tolerated in previous studies and has shown significant improvement in symptoms in patients with severe depression. In studies on Alzheimer's and dementia, the medication showed preliminary improvement in specific disease symptoms. In addition to AXS-05, the company is also working on the development of AXS-12, a drug for the treatment of narcolepsy, and AXS-09, a combination of two known drugs for the treatment of migraines. In summary, Axsome Therapeutics Inc. is a biopharmaceutical company focused on the development of novel therapies for the treatment of severe psychiatric and neurological disorders. The company has developed a proprietary technology platform that allows for cost-effective optimization and rapid development of drug candidates. Axsome Therapeutics is divided into several business areas and has several products in the pipeline at different stages of clinical development. The most advanced product is the antidepressant AXS-05, which is currently being tested in Phase III trials for the treatment of depression and Alzheimer's disease. Axsome Therapeutics ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Debt Details

Understanding Axsome Therapeutics's Debt Structure

Axsome Therapeutics's total debt refers to the cumulative financial obligations the company owes to external parties. This can include short-term and long-term borrowings, bonds, loans, and other financial instruments. Assessing the company's debt levels is crucial for evaluating its financial health, risk profile, and ability to fund operations and expansions.

Year-to-Year Comparison

Analyzing Axsome Therapeutics's debt structure over the years provides insights into the firm’s financial strategy and stability. A reduction in debt can indicate financial strength and operational efficiency, while an increase may signal growth investments or potential financial challenges ahead.

Impact on Investments

Investors pay close attention to Axsome Therapeutics’s debt levels as they can influence the company’s risk and return profiles. Excessive debt can lead to financial strain, while moderate and well-managed debt can be a catalyst for growth and expansion, making it a critical aspect of investment evaluations.

Interpreting Debt Fluctuations

Shifts in Axsome Therapeutics’s debt levels can be attributed to various operational and strategic factors. An increase in debt might be geared towards funding expansion projects or enhancing operational capacity, while a decrease may indicate profit realizations or an approach to minimize financial risk and leverage.

Frequently Asked Questions about Axsome Therapeutics stock

What is the debt of Axsome Therapeutics this year?

Axsome Therapeutics has a debt level of -208.12 USD this year.

What was the debt of Axsome Therapeutics compared to the previous year?

The debt of Axsome Therapeutics has increased by 95.42% compared to the previous year increased.

What are the consequences of high debt for investors in Axsome Therapeutics?

High debt can pose a risk for investors of Axsome Therapeutics, as it can weaken the company's financial position and hinder its ability to fulfill its obligations.

What are the consequences of low debt for investors of Axsome Therapeutics?

Low debt means that Axsome Therapeutics has a strong financial position and is able to fulfill its obligations without overburdening its finances.

How does an increase in debt from Axsome Therapeutics affect the company?

An increase in debt of Axsome Therapeutics can adversely affect the financial condition of the company and result in a higher burden on its finances.

How does a reduction of debt of Axsome Therapeutics affect the company?

A reduction in debt of Axsome Therapeutics can strengthen the company's financial position and improve its ability to meet its financial obligations.

What are some factors that influence the debt of Axsome Therapeutics?

Some factors that can influence the debt of Axsome Therapeutics include investments, acquisitions, operating costs, and revenue development.

Why are the debts of Axsome Therapeutics so important for investors?

The debts of Axsome Therapeutics are important for investors as they serve as an indicator of the company's financial stability. It provides investors with information on how the company fulfills its financial obligations.

What strategic measures can Axsome Therapeutics take to change the debt?

To change the debt, Axsome Therapeutics can take measures such as cost savings, increasing revenue, selling assets, making investments, or forming partnerships. It is important for the company to conduct a thorough review of its financial situation to determine the best strategic actions to change its debt.

How much dividend does Axsome Therapeutics pay?

Over the past 12 months, Axsome Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Axsome Therapeutics is expected to pay a dividend of 0 USD.

What is the dividend yield of Axsome Therapeutics?

The current dividend yield of Axsome Therapeutics is .

When does Axsome Therapeutics pay dividends?

Axsome Therapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Axsome Therapeutics?

Axsome Therapeutics paid dividends every year for the past 0 years.

What is the dividend of Axsome Therapeutics?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Axsome Therapeutics located?

Axsome Therapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von Axsome Therapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Axsome Therapeutics from 9/29/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 9/29/2024.

When did Axsome Therapeutics pay the last dividend?

The last dividend was paid out on 9/29/2024.

What was the dividend of Axsome Therapeutics in the year 2023?

In the year 2023, Axsome Therapeutics distributed 0 USD as dividends.

In which currency does Axsome Therapeutics pay out the dividend?

The dividends of Axsome Therapeutics are distributed in USD.